A brief pulse of rapamycin before the onset of aging extended lifespan by triggering lasting increases in autophagy. The authors called this phenomenon "rapamycin memory." Elevated autophagy was accompanied by increased levels of LManV and lysozyme in fruit flies, in intestinal enterocytes in female fly models, and its Man2B1 homologue in mice. In mice, a 3-month treatment in early adulthood had the same effect as chronic treatment, even 6 months after rapamycin was withdrawn. In the study published in the Aug. 29, 2022, issue of Nature Aging and led by researchers at the Max Planck Institute, scientists showed that the lifespan-increasing response to rapamycin treatment decreased with the age at which treatment is started.
Dysregulation of complement activation plays a key role in the pathophysiology of several diseases, which makes it an attractive therapeutic target. C3 has an important role and central position within the signaling cascade, and is a potential target for therapy.
Tranquis Therapeutics Inc. has announced preclinical data on the antiaging effects of TQS-168, a small-molecule modulator of PGC-1alpha (peroxisome proliferator-activated receptor-gamma coactivator 1-alpha).
The structure of a potent and selective TYK2 inhibitor, NDI-034858 (NTX-973), which was found clinically effective in autoimmune and inflammatory diseases, was disclosed for the first time by researchers from Nimbus Therapeutics LLC.
Researchers have created mouse embryos entirely from stem cells in vitro that formed a brain and a beating heart and lay the foundations for all the other organs of the body.
The synthetic embryos faithfully mimic the development of their natural counterparts in utero for 8.5 days, before hitting a roadblock and becoming disorganized.
Treating mice with butyrate, a short-chain fatty acid that is normally produced by beneficial gut microbes, prevented anaphylactic shock in allergic mice when they were exposed to peanuts after treatment. It also reduced inflammation in animals with colitis.
Treating mice with butyrate, a short-chain fatty acid that is normally produced by beneficial gut microbes, prevented anaphylactic shock in allergic mice when they were exposed to peanuts after treatment. It also reduced inflammation in animals with colitis.
Scientists have discovered an RNA-based mechanism that is involved in core hallmarks of a number of accelerated aging conditions and shown that therapies targeting this RNA reverses some of these hallmarks in human cells and extend life spans in mouse models.
Paradigm Biopharmaceuticals Ltd. announced a AU$66 million (US$46.39 million) capital raise to fund its phase III pivotal trial for injectable Zilosul (pentosan polysulfate) to treat osteoarthritis of the knee.
RSS
